Key facts
- This page summarizes Elizabeth A. Barrett's Form 4 filing for UroGen Pharma Ltd. (URGN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Jul 2025, 16:08.
Elizabeth A. Barrett - 28 Jul 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)
- Reporting relationship
- Chief Executive Officer
- Issuer ticker
- URGN
- Reported as of
- 28 Jul 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Jul 2025, 16:08:22 UTC
- Prior SEC filing
- 23 Jun 2025
- Next SEC filing
- 31 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason D. Smith, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Elizabeth A. Barrett filed Form 4 for UroGen Pharma Ltd. (URGN) on 30 Jul 2025.
Change
- Previous filing in this sequence was filed on 23 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001764157
Primary reporting owner
Barrett Elizabeth A.
- Relationship
- Chief Executive Officer
- Address
- 400 ALEXANDER PARK DRIVE, PRINCETON
- Signature
- /s/ Jason D. Smith, Attorney-in-Fact
- Signature date
- 30 Jul 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
URGN
transaction
Derivative
Performance Stock Units
Award
- Transaction value
- $0
- Shares
- +87,615
- Change %
- Price
- $0.000000
- Shares after
- 87,615
- Date
- 28 Jul 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 87,615
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer.
Footnote F2
Represents performance stock units ("PSUs") granted to the reporting person on January 31, 2024 that were earned upon the achievement of a corporate milestone event. These PSUs remain subject to continued service through December 31, 2025, at which time they will vest and settle in ordinary shares.